Perioperative management of apixaban in patients with advanced CKD undergoing a planned invasive procedure.
Journal Information
Full Title: Blood Adv
Abbreviation: Blood Adv
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
2/6
33.3% Transparent
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
Data Sharing
Code Sharing
COI Disclosure
Evidence found in paper:
"Conflict-of-interest disclosure: J.R.S. has received in-kind laboratory support from Diagnostica Stago. M.M.S. has provided consultancy/received speaker fees from AstraZeneca, Bayer, GlaxoSmithKline, and Otsuka. J.D. has conducted consultancy/advisory board work for AstraZeneca, Cytosorb, PhaseBio, Servier, Leo Pharma, and Pfizer. M.C. has received research funding from Leo Pharma and Pfizer, in addition to honoraria from Bristol Myers Squibb, Valeo Pharma, Leo Pharma, Sanofi, and Servier. The remaining authors declare no competing financial interests."
Funding Disclosure
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025